The six-minute walk test (6MWT) is a sub-maximal exercise test used clinically as a measure of functional capacity. With the emergence of advanced sensors, 6MWTs were commonly performed remotely via smartphones and other devices. The My Heart Counts Cardiovascular Health Study is a smartphone application that serves as a digital platform for studies of human cardiovascular health. It has been used to perform 30,475 6MWTs on 25,539 unique participants. Here, we report on the associations of demographic and clinical variables with 6MWT distance at baseline (N=4,576), validating prior associations with male gender, height, and baseline physical activity with 6MWT distance in multivariable regression analysis. We also report associations of 6MWT baseline distance with working status (+26.8m +5.2m, P<0.001) and feeling depressed (−3.78m, +0.79m, P<0.001). In a subset of participants who conducted repeat 6MWTs separated by at least 1-week but no greater than 3-months (N=2,269), we found that use of the My Heart Counts app resulted in a statistically significant increase in 6MWT distance (+21.5m +5.72m, P <0.001). Finally, we present the public data release of our 30,475 6MWTs and the launch of a webpage-based data viewer of summary-level statistics, to compare the relative health of an individual by their age, gender, and chronic disease status. Given the importance of 6MWTs in assessment of functional capacity, our publicly-available data will serve an important purpose as a healthy and disease-specific reference for investigators worldwide.
Purpose of review: In this review, we discuss the importance of digital health equity and how social determinants of health (and intersectionality with race, ethnicity, and gender) affect cardiovascular health-related outcomes in digital health trials. We propose strategies to improve digital health equity as we move to a digitally-connected world for healthcare applications and beyond. Recent findings: Digital health has immense promise to improve population health by reaching individuals in their homes, at their preferred times. However, initial data demonstrate decreased patient engagement and worse cardiovascular outcomes for racial and ethnic minorities, leading to unequal uptake of digital health technologies. In addition, while women generally have higher uptake of technology, they are less likely to be referred by clinicians for digital health interventions. We highlight several exemplar trials and analyze their methodology for replication in future digital health research. Summary: The promise of digital health equity has not been reached due to exclusionary practices. Specific focus must be placed on societal/governmental policies that enable digital inclusion, particularly of racial and ethnic minority populations and women, to ensure that the expansion of digital health technologies does not exacerbate existing health disparities.
We describe real-world use of mavacamten in 50 patients with oHCM. Consistent with EXPLORER-HCM and VALOR-HCM, we report significant improvement in wall thickness, mitral regurgitation, left ventricular outflow tract obstruction and NYHA class. Moreover, in our center’s experience, neither arrhythmia burden, nor contractility have worsened in the vast majority of patients: We note a clinically insignificant mean decrease in left ventricular ejection fraction (LVEF), with only two patients requiring temporary mavacamten discontinuance for LVEF < 50%. Adverse events were rare, unrelated to mavacamten itself, and seen solely in patients with disease too advanced to have been represented in clinical trials. Our multidisciplinary pathway enabled us to provide a large number of patients with a novel closely-monitored therapeutic within just a few months of commercial availability. These data lead us to conclude that mavacamten, as a first-in-class cardiac myosin inhibitor, is safe and efficacious in real-world settings.
BACKGROUND: Cardiorespiratory fitness (CRF), measured by peak oxygen uptake (VO 2 peak), is a strong predictor of mortality. Despite its widespread clinical use, current reference equations for VO 2 peak show distorted calibration in obese individuals. Using data from the Fitness Registry and the Importance of Exercise National Database (FRIEND), we sought to develop novel reference equations for VO 2 peak better calibrated for overweight/obese individuals - in both males and females, by considering body composition metrics. METHODS AND RESULTS: Graded treadmill tests from 6,836 apparently healthy individuals were considered in data analysis. We used the National Health and Nutrition Examination Survey equations to estimate lean body mass (eLBM) and body fat percentage (eBF). Multivariable regression was used to determine sex-specific equations for predicting VO 2 peak considering age terms, eLBM and eBF. The resultant equations were expressed as VO 2 peak (male) = 2633.4 + 48.7✕eLBM (kg) - 63.6✕eBF (%) - 0.23✕Age 2 (R 2 =0.44) and VO 2 peak (female) = 1174.9 + 49.4✕eLBM (kg) - 21.7✕eBF (%) - 0.158✕Age 2 (R 2 =0.53). These equations were well-calibrated in subgroups based on sex, age and body mass index (BMI), in contrast to the Wasserman equation. In addition, residuals for the percent-predicted VO 2 peak (ppVO 2 ) were stable over the predicted VO 2 peak range, with low CRF defined as < 70% ppVO 2 and average CRF defined between 85-115%. CONCLUSIONS: The derived VO 2 peak reference equations provided physiologically explainable and were well-calibrated across the spectrum of age, sex and BMI. These equations will yield more accurate VO 2 peak evaluation, particularly in obese individuals.